LAI Expert Consensus Statement on Management of Dyslipidemia in Indians 2016. JAPI 2016 Mar;64:7-52.
Consensus statement by the American association of clinical endocrinologists and American college of endocrinology of the comprehensive type 2 diabetes management algorithm — 2017 executive summary. Endocr Pract 2017 Feb;23(2):207-227.
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014 Jul;371(1):22-31.
Variation in ANGPTL4 and risk of coronary heart disease: the atherosclerosis risk in communities study. Metabolism 2008 Nov;57(11):1591-1596.
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 Apr;362(17):1563-1574.
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011 Aug;217(2):492-498.
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 Jun;372:2387-2397.
Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Expert Rev Clin Pharmacol 2016 Mar;9(5):655-663.
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012 Nov;126(19):2283-2292.
A two-step binding mode of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 2011 Feb;286(7):5464-5470.
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 Jun;34(2):154-156.
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res 2011 Apr;52(4):679-687.
